A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-14 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Medieval philosophers who used Aristotelian concepts frequently distinguished between substantial forms and accidental forms. A substance necessarily possesses at least one substantial form. It may also possess a variety of accidental forms. For Aristotle, a "substance" (ousia) is an individual thing—for example, an individual man or an individual horse. Within every physical substance, the substantial form determines what kind of thing the physical substance is by actualizing prime matter as individualized by the causes of that thing's coming to be. For instance, the chick comes to be when the substantial form of chickens actualizes the hen's egg and that actualization is possible insofar as that egg is in potency to being actualized both as a chicken due to the receptivity of its prime matter to the substantial form of chickens and into a chick with certain colored feathers due to the individualization of the egg given by its parents. So while the individualized matter determines individualized properties, the substantial form determines essential properties. The substantial form of a substance S consists of its essence and essential properties (the properties that S needs in order to be the kind of substance that S is). Substantial change destroys the ability of a substantial form to actualize individualized prime matter without affecting prime matter's ability to be actualized by a new substantial form; e.g., when the wolf eats the chick, the chick's rearranged matter becomes part of the wolf, and is thence animated by the wolf's substantial form.
=== Pest risk analysis === As of 2019 the East African Community considers P. aeruginosa to be a quarantine concern because of the presence of Phaseolus vulgaris–pathogenic strains of P. aeruginosa in Kenya for the rest of the area. A pest risk analysis by the EAC was based on this bacterium's CABI's Crop Protection Compendium listing, following Kaaya & Darji 1989's initial detection in Kenya.
== Natural selection in humans == The malaria parasite can exert a selective pressure on human populations. This pressure has led to natural selection for erythrocytes carrying the sickle cell hemoglobin gene mutation (Hb S)—causing sickle cell anaemia—in areas where malaria is a major health concern, because the condition grants some resistance to this infectious disease.
Sources: en.wikipedia.org
crosslink Also cross-link. Any chemical bond or series of bonds, normal or abnormal, natural or artificial, that connects two or more polymeric molecules to each other, creating an even larger, often structurally rigid and mechanically durable macromolecular complex. Crosslinks may consist of covalent, ionic, or intermolecular interactions, or even extensive physical entanglements of molecules, and may be reversible or irreversible; in polymer chemistry the term is often used to describe macrostructures that form predictably in the presence of a specific catalyst. In molecular biology the usage generally implies abnormal bonding (whether naturally occurring or experimentally induced) between different biomolecules (or different parts of the same biomolecule) which are ordinarily separate, especially nucleic acids and proteins. Crosslinking of DNA may occur between nucleobases on opposite strands of a double-stranded DNA molecule (interstrand), or between bases on the same strand (intrastrand), via the formation of covalent bonds that are stronger than the hydrogen bonds of normal base pairing; these are common targets of DNA repair pathways. Proteins are also susceptible to becoming crosslinked to DNA or to other proteins through bonds to specific surface residues, a process which is deliberately induced in many laboratory methods such as fixation and which can be useful for studying interactions between proteins in their native states.
The government of Portugal established on 26 November 2015 was a left-wing minority government led by Prime Minister António Costa Socialist Party, who succeeded in securing support for the government by the Left Bloc, the Portuguese Communist Party and the Ecologist Party "The Greens". This was largely confirmed in the 2019 legislative election, where the Socialist Party returned to first place, forming another left-wing minority government, this time led only by the Socialist Party. Nonetheless, Costa said he would look to continue the confidence-and-supply agreement with the Left Bloc and the Unitary Democratic Coalition.
=== Late 20th century === In the 1970s, Lionel Jaffe and Richard Nuccittelli's introduction and development of the vibrating probe, the first device for quantitative non-invasive characterization of the extracellular minute ion currents, revitalized the field. Researchers such as Joseph Vanable, Richard Borgens, Ken Robinson, and Colin McCaig explored the roles of endogenous bioelectric signaling in limb development and regeneration, embryogenesis, organ polarity, and wound healing.
Sources: en.wikipedia.org
2014 (ongoing): Nepal and Bangladesh, neonatal exposures, found in umbilical cord blood. 2019 Kenya: five brands of maize flour recalled due to contamination. 2021 US: Contamination of pet food manufactured by Midwestern Pet Food, causing the deaths of at least 70 dogs. 2021 Sri Lanka: contaminated coconut oil released for public consumption by the local government.. 2023 Makueni County, Kenya: In a cross-sectional study was used to determine the dietary aflatoxin exposure of 170 lactating mothers breastfeeding children aged 6 months and below. This involved the aflatoxin analysis of maize-based cooked food sample which was in their staple foods. Aflatoxins were determined using high-performance liquid chromatography and enzyme-linked immunosorbent assay. About 46% of the mothers were from low-income households, and 48.2% had not attained the basic level of education. A generally low dietary diversity was reported among 54.1% of lactating mothers. Food consumption pattern was skewed towards starchy staples. Approximately 50% never treated their maize, and at least 20% stored their maize in containers that promote aflatoxin contamination. Aflatoxin was detected in 85.4% of food samples. The mean of total aflatoxin was 97.8 μg/kg (standard deviation [SD], 57.7), while aflatoxin B1 was 9.0 μg/kg (SD, 7.7).
Earlier studies found mean elimination rates of 15 mg/dL per hour for men and 18 mg/dL per hour for women, but Jones found 0.148 g/L/h and 0.156 g/L/h respectively. Although the difference between sexes is statistically significant, it is small compared to the overall uncertainty, so Jones recommends using the value 0.15 for the mean for all subjects. This mean rate is very roughly 8 grams of pure ethanol per hour (one British unit). Explanations for the gender difference are quite varied and include liver size, secondary effects of the volume of distribution, and sex-specific hormones. A 2023 study using a more complex two-compartment model with M-M elimination kinetics, with data from 60 men and 12 women, found statistically small effects of gender on maximal elimination rate and excluded them from the final model. At concentrations below 0.15-0.20 g/L, alcohol is eliminated more slowly and the elimination rate more closely follows first-order kinetics. The overall behavior of the elimination rate is described well by Michaelis–Menten kinetics. This change in behavior was not noticed by Widmark because he could not analyze low BAC levels. The rate of elimination of ethanol is also increased at very high concentrations, such as in overdose, again more closely following first-order kinetics, with an elimination half-life of about 4 or 4.5 hours (a clearance rate of approximately 6 L/hour/70 kg). This is thought to be due to increased activity of CYP2E1. Eating food in proximity to drinking increases elimination rate significantly, mainly due to increased metabolism.
=== Recoded synthetic genome === One way to achieve the encoding of multiple unnatural amino acids is by synthesising a rewritten genome. In 2010, at the cost of $40 million an organism, Mycoplasma laboratorium, was constructed that was controlled by a synthetic, but not recoded, genome. The first genetically recoded organism was created by a collaboration between George Church's and Farren Isaacs' labs, when the wild type E. coli MG1655 was recoded in such a way that all 321 known UAG stop codons were substituted with synonymous UAA codons and release factor 1 was knocked out in order to eliminate the interaction with the exogenous stop codon and improve unnatural protein synthesis. In 2019, Escherichia coli Syn61 was created, with a 4 megabase recoded genome consisting of only 61 codons instead of the natural 64. In addition to the elimination of the usage of rare codons, the specificity of the system needs to be increased as many tRNA recognise several codons
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.